Clinical efficacy and indication of acetazolamide treatment on sleep apnea syndrome.
The efficacy and indication of acetazolamide treatment on patients with sleep apnea syndrome (SAS) were discussed from assessing the changes of polysomnographic findings with the treatment in 75 SAS patients. For the patients as a whole, respiratory disorder variables improved significantly during the treatment. However, the number of acetazolamide treatment responders who showed a decrease of apnea hypopnea index (AHI) to 50% or less of the pretreatment value numbered only 34 (45.3%). The lower values of body mass index and AHI in the responder group indicated that monotherapy with acetazolamide is the treatment choice only for mild SAS cases without obesity. However, combined treatment with acetazolamide and uvulopalatopharyngoplasty was thought to be beneficial for severe cases.
Inoue
Y
Y
Department of Neuropsychiatry, Faculty of Medicine, Tottori University, Yonago, Japan.
Takata
K
K
Sakamoto
I
I
Hazama
H
H
Kawahara
R
R
D000086:Acetazolamide / Q000627:therapeutic use*; D015992:Body Mass Index; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010160:Palate, Soft / Q000601:surgery; D010614:Pharynx / Q000601:surgery; D017286:Polysomnography / Q000187:drug effects; D012891:Sleep Apnea Syndromes / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome; D014609:Uvula / Q000601:surgery
D002257:Carbonic Anhydrase Inhibitors; D000086:Acetazolamide